个性化剂量测量以指导儿科神经母细胞瘤中酸盐治疗
Kevin London1,2,3, Justine Trpezanovski1, Toby Trahair4,5,6
1Department of Nuclear Medicine, The Children's Hospital at Westmead, Sydney Children's Hospitals Network, Westmead, Sydney, NSW, Australia.
World journal of nuclear medicine
|November 12, 2025
概括
针对卢塞-177卢塞氧三甲 (LuTATE) 治疗的个性化剂量测量显示,对于治疗儿童复发性或耐药神经母细胞瘤具有前途. 这种方法优化了剂量,使得儿童癌症患者的治疗结果更好.
科学领域:
- 儿科瘤学 儿科瘤学
- 核医学是一种核医学.
- 放射性药物疗法是一种放射性药物疗法.
背景情况:
- 神经母细胞瘤是一种常见的儿童脑外固体瘤,预后可变.
- 高风险因素,如N-myc放大和动脉积症会使结果变得更糟.
- I-131 MIBG治疗是标准的,但面临成本,可用性和安全障碍.
研究的目的:
- 评估针对儿科神经母细胞瘤的卢-177卢氧三甲 (LuTATE) 疗法的个性化剂量测量疗效.
- 为了解决LuTATE在这个患者群体中的经验剂量限制.
- 探索LUTATE作为一种治疗药物与GATATE PET/CT一起用于神经母细胞瘤.
主要方法:
- 用个性化患者剂量测量来确定最佳的LuTATE剂量.
- 这项研究涉及三名患有复发或耐药神经母细胞瘤的儿科患者.
- 根据患者特定的吸收剂量计算,LuTATE被管理.
主要成果:
- 个性化剂量测量允许在儿科神经母细胞瘤中优化LuTATE剂量.
- 这种方法为实证剂量提供了一个潜在的更有效的替代方案.
- 这项研究证明了定制放射性药物治疗的可行性.
结论:
- 针对LuTATE治疗的个性化剂量测量是儿科神经母细胞瘤的一个有前途的策略.
- 这种方法可以克服先前研究中经验剂量的无效性.
- 需要进行进一步的研究,以确定LuTATE在神经母细胞瘤治疗中的作用.
更多相关视频
07:57Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
Published on: March 24, 2022
3.1K
09:44Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
10.5K
相关概念视频
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
197
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
197
01:29Drug Dosing: Infants and Children
237
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
237